Summary
Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on March 8, 2022, primarily to reaffirm its financial guidance for the full year 2022. The company expects net income to be greater than $26.75 per share, which includes approximately $1.50 per share in net unfavorable items. Excluding these specific items, the adjusted net income guidance remains strong, projected to be greater than $28.25 per share. This reaffirmation comes as company officers are scheduled to engage with investors over the coming weeks. While the filing does not introduce new operational developments, it serves to reinforce management's confidence in the company's financial trajectory for the year. Investors should note that the information provided is subject to forward-looking statement disclaimers and potential risks outlined in the company's other SEC filings.
Key Highlights
- 1Elevance Health reaffirms its 2022 full-year net income guidance.
- 2Projected net income for FY2022 is greater than $26.75 per share.
- 3Includes approximately $1.50 per share in expected net unfavorable items.
- 4Excluding unfavorable items, adjusted net income guidance is greater than $28.25 per share.
- 5The company's officers will be speaking with investors in the coming weeks.
- 6The filing is made under Regulation FD Disclosure (Item 7.01).
- 7Information furnished is not deemed 'filed' for Section 18 purposes.